Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

NCT04101331 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral T Cell Lymphoma
Transformed Mycosis Fungoides

Interventions

DRUG: AFM13

Sponsor

Affimed GmbH